Linvo, Tec/Tal, & BiTEs – Oh My! Making Sense of Bispecific Antibodies in MM
Linvo, Tec/Tal, & BiTEs – Oh My! Making Sense of Bispecific Antibodies in MM
Related Articles
Peeling Back the Layers: Recurrent Talquetamab Skin Toxicity After Supportive Stem Cell Boost in Multiple Myeloma – PubMed
Bispecific antibodies have meaningfully expanded the therapeutic armentarium in multiple myeloma. Talquetamab is a CD3+ T cell redirecting antibody targeting GPRC5D, which is expressed on…
Significance of the pee-value: relevance of 24-hour urine studies for patients with myeloma
International Myeloma Working Group (IMWG) response criteria require refrigerated 24-hour urine specimens for most patients. However, given that serum free light chain testing has been…
The utility of repeat kidney biopsy in systemic immunoglobulin light chain amyloidosis – PubMed
Background: The diagnostic utility of repeat kidney biopsy in AL amyloidosis patients in complete (CR) or very good partial hematologic response (VGPR) but with renal…
What Are the Benefits of Myeloma Consults and Second Opinions? – Patient Empowerment Network
What can myeloma consults and second opinions bring to patients? Dr. Ola Landgren shares his perspective on the benefits.
Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma
Amp(1q), HRCA ≥2, high CTC levels, and a longer time to reach first MRD negativity are significant predictors of unsustained MRD negativity.Maintenance treatmen
Listen to: The Supreme Court hears Trump’s unprecedented immunity claim
Plus, a bone-marrow-transplant revolution, and why fewer college football players are entering the NFL draft.
Program Guide – ASCO Meeting Program Guide
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Program Guide – ASCO Meeting Program Guide
The 2024 ASCO Annual Meeting is funded through Conquer Cancer®, the ASCO Foundation, by these sponsorship donors. Bristol Myers Squibb Daiichi Sankyo,
Our Journey | Emily Whitehead Foundation
Emily Whitehead has been in remission since 2012 after receiving CAR T-cell therapy to treat her leukemia.
Physician perceptions regarding carfilzomib dosing in multiple myeloma
This value you provided is not a number. Please try again. This value you provided is not an integer. Please try again. The value enter…